Dyax/Genzyme Phase II Hereditary Angioedema Therapy On Clinical Hold; FDA Questioning Rat Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies submitted to FDA primate data and interim results from the now-halted Phase II EDEMA2 study. The rat deaths could be related to DX-88 bolus administration, Dyax suggested.
You may also be interested in...
Dyax DX-88 Anticipated Approval Pushed Back to 2008
Company will conduct a confirmatory placebo-controlled trial following FDA recommendation.
Dyax DX-88 Anticipated Approval Pushed Back to 2008
Company will conduct a confirmatory placebo-controlled trial following FDA recommendation.
Dyax DX-88 Submission Likely Postponed For Additional Dosing Study
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.